July 21, 2017 01:32 PM EDT
R&D

Bay­er’s block­buster pipeline promis­es bro­ken by a PhII set­back for top can­cer drug

John Carroll

Editor & Founder

Bay­er tout­ed its ex­per­i­men­tal can­cer drug ane­tum­ab rav­tan­sine as a $2 bil­lion-plus peak earn­er in the mak­ing for the phar­ma com­pa­ny. And it just …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times